Multiple Sclerosis

A multimodal AI approach could highlight areas in the brain that were associated with cognitive worsening in patients with MS.

The 5-year prediction of MS progression, defined by clinical and objective measurements, was possible with 2 machine learning tools.

Patients who were treatment naive or had switched to rituximab saw short-term results of reduced disease activity in multiple sclerosis.

Despite decreases in therapy use, hospitalizations for multiple sclerosis and neurologist visits were not affected significantly.

Lower actual wearable use was found in patients with multiple sclerosis (MS) despite comparable intentions to use the wearable technology.

Smoking cessation, abnormal weight, and socioeconomic deprivation were all associated with mortality in multiple sclerosis.

Patients with multiple sclerosis valued both occupational therapy and physiotherapy as means of addressing their condition.

Severe COVID-19 was rare in patients with multiple sclerosis even when vaccine responses were impaired.

Persistent high-level EBNA-1 peptide antibody titers could be used to identify multiple sclerosis (MS) vs neuromyelitis optica spectrum disorder (NMOSD).

Environmental factors were a barrier to participation in community activities among people with multiple sclerosis, even after adjusting for personal factors like disease severity.

A prospective study of first-degree relatives of patients with MS found that this high-risk population faces significantly elevated incidence rates and has strong willingness to participate in prevention trials.

Two analyses revealed significant delays and systemic barriers in the MS diagnostic journey alongside substantial clinical and economic burden in primary progressive MS.

Discover the latest breakthroughs in multiple sclerosis treatments and research developments shaping the future of MS care in 2025.

Explore the top 5 insights on managed care, public health policy, and emerging health trends shaping 2025's health care landscape.

In-home step training for multiple sclerosis showed no improvement in ankle proprioception or muscle performance, highlighting challenges in exercise adherence.

Developers say more accurate automated multiple sclerosis lesion segmentation can improve research and patient care.

Investigators will test whether adding anodal transcranial direct current stimulation to exergame-based rehabilitation improves short- and long-term cognitive outcomes in 80 adults with multiple sclerosis.

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

New research comparing the safety profiles of the 2 multiple sclerosis therapies suggests ocrelizumab is associated with lower rates of all-cause hospitalization and hypogammaglobulinemia.

Diet and metabolic health may have causal effects on MS development, suggesting that a healthy weight, controlling glucose levels, and reducing red meat intake may delay or prevent onset.

The study underscores the importance of repeat testing in cases where myelin oligodendrocyte glycoprotein immunoglobulin G tests are borderline.

Radiomic assessment has been used to distinguish multiple sclerosis from similar disorders, and it might also be useful in identifying MS stages and subtypes.

Structural and microbial findings point to a potential nasal-brain immune connection in patients with multiple sclerosis (MS).

Lesion-based disconnectome mapping suggests that the pattern, not the quantity, of brain damage determines cognitive outcomes in patients with MS.

Researchers developed a first-of-its-kind panel to track receptor expression and predict therapy response.